文献速递银屑病与炎症性皮肤病

银屑病严重程度:常用临床阈值可能无法充分反映患者影响

Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-12-09

本研究通过系统综述2000年1月至2017年6月发表的轻中度银屑病随机对照试验,评估常用严重程度阈值(PASI 10-12和BSA 10)是否与患者报告的DLQI数据一致。结果显示,DLQI>10的患者平均加权BSA为7.6、PASI为8.7,均低于常用阈值。结论指出PASI或BSA低于10的患者也可能有显著生活质量损害,单用客观指标可能无法全面反映疾病影响。

要点

  • PASI或BSA低于10的患者仍可能出现重大生活质量损害。
  • 常用阈值PASI 10-12和BSA 10可能低估疾病对患者的影响。
  • 评估严重程度时应结合患者报告的DLQI,而非仅用客观指标。

核心结论

  • PASI或BSA评分低于10的患者也可能有显著生活质量损害。
  • 单独使用BSA和PASI等客观指标可能无法全面反映疾病严重程度的影响。

研究设计与样本

  • 系统综述纳入2000年1月至2017年6月发表的、纳入轻中度患者的随机对照试验,评估基线时医生与患者报告的严重程度指标之间的相关性。

主要发现

  • 对于DLQI>10的受试者组,平均加权BSA为7.6(范围7.1-8.4),平均加权DLQI为11(范围10.2-12.2)。
  • 对于DLQI>10的患者,平均加权PASI为8.7(范围7.1-10.1),平均加权DLQI为10.9(范围10.1-12.2)。

关键数值与推荐

  • 常用最低严重程度阈值定义为PASI 10或12。
  • 常用中度银屑病阈值包括PASI 10-12和BSA 10。
  • DLQI>10表示生活质量受到高影响。

临床怎么用

  • 临床评估银屑病严重程度时,应结合患者报告的DLQI,避免仅依赖PASI或BSA。
  • 对于PASI或BSA低于10但DLQI较高的患者,应考虑其疾病影响可能被低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis severity is usually evaluated using quantitative and qualitative measures, including per cent body surface area (BSA) involvement, the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI), a patient-reported questionnaire. However, standardized definitions for psoriasis severity categories have not been well established. A PASI of 10 or 12 has remained the minimal severity threshold defining eligibility for psoriasis treatments. In the present study, the validity of this cut-off was re-evaluated in the context of quality of life. OBJECTIVE: To determine whether the thresholds commonly used to define moderate psoriasis (PASI of 10-12 and BSA of 10) are supported by patient-reported DLQI data. METHODS: A systematic review of randomized controlled trials that enrolled mild or moderate patients published between January 2000 and June 2017 was used to assess correlations between provider and patient-generated severity at baseline. RESULTS: For subject groups with high impact on quality of life (DLQI > 10), the mean weighted BSA was 7.6 (Range: 7.1-8.4) and the mean weighted DLQI was 11 (Range: 10.2-12.2). Similarly, the mean weighted PASI for patients with DLQI > 10 was 8.7 (Range: 7.1-10.1) and the mean weighted DLQI was 10.9 (Range: 10.1-12.2). CONCLUSION: Patients with PASI or BSA scores less than 10 can have major quality of life impairment. In general, the objective measures of BSA and PASI alone, when excluding DLQI, may not fully capture the impact of disease severity.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Golbari NM, van der Walt JM, Blauvelt A, et al. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol. 2020. PMID: 32978847. doi:10.1111/jdv.16966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。